Bacterial resistance to antibiotics: Modified target sites

Advanced Drug Delivery Reviews

Volumn 57, Issue 10, 2005, Pages 1471-1485

  Lambert, Peter A ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Antibiotics; Bacterial resistance; Genetic exchange; Modified targets; Resistance genes

Indexed keywords

BACTERIA; DNA; GENES; GENETIC ENGINEERING; RNA;

ENTEROCCOCCI ENCODING; GLYCOPEPTIDES; RIFAMYCINS; STAPHYLOCCOCUS;

ANTIBIOTICS;

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; COLISTIN; DALBAVANCIN; FUSIDIC ACID; HEXACHLOROPHENE; ISONIAZID; LINCOSAMIDE; LINEZOLID; MACROLIDE; MIKAMYCIN B; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; POLYMYXIN B; PSEUDOMONIC ACID; PYRAZINAMIDE; PYRIMETHAMINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAMYCIN; TEICOPLANIN; TELAVANCIN; TRICLOSAN; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VANCOMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL GENE; BACTERIAL STRAIN; BINDING AFFINITY; CELL WALL; CHEMICAL MODIFICATION; CHROMOSOME; CONJUGATION; DRUG MECHANISM; ENTEROCOCCUS; GENE MUTATION; GENE TRANSFER; GENETIC TRANSDUCTION; GENETIC TRANSFORMATION; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; HUMAN; LISTERIA MONOCYTOGENES; METHYLATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; REVIEW; RIBOSOME; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SYNTHESIS; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; BINDING SITES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MUTATION; PENICILLIN-BINDING PROTEINS;

EID: 22144437663     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2005.04.003     Document Type: Review

References (149)

1. M.C. Enright, D.A. Robinson, G. Randle, E.J. Feil, H. Grundmann, and B.G. Spratt The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA) Proc. Natl. Acad. Sci. U. S. A. 99 2002 7687 7692
2. T. Ito, K. Okuma, X.X. Ma, H. Yuzawa, and K. Hiramatsu Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: genomic island SCC Drug Resist. Updat. 6 2003 41 52
3. M.C. Enright The evolution of a resistant pathogen-the case of MRSA Curr. Opin. Pharmacol. 3 2003 474 479
4. D.C. Oliveira, and H. de Lencastre Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus Antimicrob. Agents Chemother. 46 2002 2155 2161
5. D. Golemi-Kotra, S.O. Meroueh, C. Kim, S.B. Vakulenko, A. Bulychev, A.J. Stemmler, T.L. Stemmler, and S. Mobashery The importance of a critical protonation state and the fate of the catalytic steps in class A β-lactamases and penicillin-binding proteins J. Biol. Chem. 279 2004 34665 34673
6. W.P. Lu, Y. Sun, M.D. Bauer, S. Paule, P.M. Koenigs, and W.G. Kraft Penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus: kinetic characterization of its interactions with β-lactams using electrospray mass spectrometry Biochemistry 38 1999 6537 6546
7. C. Fuda, M. Suvorov, S.B. Vakulenko, and S. Mobashery The basis for resistance to β-lactam antibiotics by penicillin-binding protein 2a (PBP2a) of methicillin-resistant Staphylococcus aureus J. Biol. Chem. 279 39 2004 40802 40806
8. D. Lim, and N.C. Strynadka Structural basis for the β lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus Nat. Struct. Biol. 9 2002 870 876
9. E. Gordon, N. Mouz, E. Duee, and O. Dideberg The crystal structure of the penicillin-binding protein 2x from Streptococcus pneumoniae and its acyl-enzyme form: implication in drug resistance J. Mol. Biol. 299 2000 477 485
10. Y. Iizawa, J. Nagai, T. Ishikawa, S. Hashiguchi, M. Nakao, A. Miyake, and K. Okonogi In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599 J. Infect. Chemother. 10 2004 146 156
11. M. Tsuji, M. Takema, H. Miwa, J. Shimada, and S. Kuwahara In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models Antimicrob. Agents Chemother. 47 2003 2507 2512
12. F. Malouin, J. Blais, S. Chamberland, M. Hoang, C. Park, C. Chan, K. Mathias, S. Hakem, K. Dupree, E. Liu, T. Nguyen, and M.N. Dudley RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal β-lactamases Antimicrob. Agents Chemother. 47 2003 658 664
13. R.N. Jones, L.M. Deshpande, A.H. Mutnick, and D.J. Biedenbach In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci J. Antimicrob. Chemother. 50 2002 915 932
14. J. Vouillamoz, J.M. Entenza, P. Hohl, and P. Moreillon LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus Antimicrob. Agents Chemother. 48 2004 4322 4327
15. M. Kurazono, T. Ida, K. Yamada, Y. Hirai, T. Maruyama, E. Shitara, and M. Yonezawa In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci Antimicrob. Agents Chemother. 48 2004 2831 2837
16. Y. Ueda, and M. Sunagawa In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1-β-methylcarbapenems with potent activities against multiresistant gram-positive bacteria Antimicrob. Agents Chemother. 47 2003 2471 2480
17. L. Ferrari, L. Iavarone, S. Braggio, and E. Di Modugno In vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem Antimicrob. Agents Chemother. 47 2003 770 776
18. T. Grebe, and R. Hakenbeck Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of β-lactam antibiotics Antimicrob. Agents Chemother. 40 1996 829 834
19. K. Nagai, T.A. Davies, M.R. Jacobs, and P.C. Appelbaum Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci Antimicrob. Agents Chemother. 46 2002 1273 1280
20. K. Kosowska, M.R. Jacobs, S. Bajaksouzian, L. Koeth, and P.C. Appelbaum Alterations of penicillin-binding proteins 1A, 2X, and 2B in Streptococcus pneumoniae isolates for which amoxicillin MICs are higher than penicillin MICs Antimicrob. Agents Chemother. 48 2004 4020 4022
21. C.G. Dowson, T.J. Coffey, and B.G. Spratt Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to β-lactam antibiotics Trends Microbiol. 2 1994 361 366
22. T.J. Coffey, C.G. Dowson, M. Daniels, and B.G. Spratt Genetics and molecular biology of β-lactam-resistant pneumococci Microb. Drug Resist. 1 1995 29 34
23. A.G. Barbour Properties of penicillin-binding proteins in Neisseria gonorrhoeae Antimicrob. Agents Chemother. 19 1981 316 322
24. B.G. Spratt Hybrid penicillin-binding proteins in penicillin-resistant strains of Neisseria gonorrhoeae Nature 332 1988 173 176
25. P.A. Ropp, M. Hu, M. Olesky, and R.A. Nicholas Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae Antimicrob. Agents Chemother. 46 2002 769 777
26. K.E. Hagman, W. Pan, B.G. Spratt, J.T. Balthazar, R.C. Judd, and W.M. Shafer Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system Microbiology 141 1995 611 622
27. L.D. Bowler, Q.Y. Zhang, J.Y. Riou, and B.G. Spratt Interspecies recombination between the penA genes of Neisseria meningitidis and commensal Neisseria species during the emergence of penicillin resistance in N. meningitidis: natural events and laboratory simulation J. Bacteriol. 176 1994 333 337
28. B.G. Spratt, Q.-Y. Zhang, D.M. Jones, A. Hutchison, J.A. Brannigan, and C.G. Dowson Recruitment of a penicillin binding protein gene from Neisseria flavescens during the emergence of penicillin resistance in Neisseria meningitidis Proc. Natl. Acad. Sci. U. S. A. 86 1989 8988 8992
29. B.G. Spratt, L.D. Bowler, Q.-Y. Zhang, J. Zhou, and J. Maynard Smith Role of inter-species transfer of chromosomal genes in the evolution of penicillin resistance in pathogenic and commensal Neisseria species J. Mol. Evol. 34 1992 115 125
30. H.Y. Chen, and J.D. Williams Penicillin-binding proteins in Streptococcus faecalis and S. faecium J. Med. Microbiol. 23 1987 141 147
31. R. Fontana, M. Aldegheri, M. Ligozzi, H. Lopez, A. Sucari, and G. Satta Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium Antimicrob. Agents Chemother. 38 1994 1980 1983
32. T. Rybkine, J.L. Mainardi, W. Sougakoff, E. Collatz, and L. Gutmann Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of β-lactam resistance J. Infect. Dis. 178 1998 159 163
33. E. Sauvage, F. Kerff, E. Fonze, R. Herman, B. Schoot, J.P. Marquette, Y. Taburet, D. Prevost, J. Dumas, G. Leonard, P. Stefanic, J. Coyette, and P. Charlier The 2.4-A crystal structure of the penicillin-resistant penicillin-binding protein PBP5fm from Enterococcus faecium in complex with benzylpenicillin Cell. Mol. Life Sci. 59 2002 1223 1232
34. K. Ubukata, Y. Shibasaki, K. Yamamoto, N. Chiba, K. Hasegawa, Y. Takeuchi, K. Sunakawa, M. Inoue, and M. Konno Association of amino acid substitutions in penicillin-binding protein 3 with β-lactam resistance in β-lactamase-negative ampicillin-resistant Haemophilus influenzae Antimicrob. Agents Chemother. 45 2001 1693 1699
35. V. Matic, B. Bozdogan, M.R. Jacobs, K. Ubukata, and P.C. Appelbaum Contribution of β-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in β-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae J. Antimicrob. Chemother. 52 2003 1018 1021
36. H. Wu, X.D. Shi, H.T. Wang, and J.X. Liu Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin J. Antimicrob. Chemother. 46 2000 121 123
37. R. Paul, S. Postius, K. Melchers, and K.P. Schafer Mutations of the Helicobacter pylori genes rdxA and pbp1 cause resistance against metronidazole and amoxicillin Antimicrob. Agents Chemother. 45 2001 962 965
38. T. Okamoto, H. Yoshiyama, T. Nakazawa, I.D. Park, M.W. Chang, H. Yanai, K. Okita, and M. Shirai A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori J. Antimicrob. Chemother. 50 2002 849 856
39. C. Neuwirth, E. Siebor, J.M. Duez, A. Pechinot, and A. Kazmierczak Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins J. Antimicrob. Chemother. 36 1995 335 342
40. M. Gehrlein, H. Leying, W. Cullmann, S. Wendt, and W. Opferkuch Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins Chemotherapy 37 1991 405 412
41. F. Bellido, C. Veuthey, J. Blaser, A. Bauernfeind, and J.C. Pechere Novel resistance to imipenem associated with an altered PBP-4 in a Pseudomonas aeruginosa clinical isolate J. Antimicrob. Chemother. 25 1990 57 68
42. G.J. van Asselt, G. de Kort, and J.A. van de Klundert Differences in penicillin-binding protein patterns of penicillin tolerant and non-tolerant group A streptococci J. Antimicrob. Chemother. 35 1995 67 74
43. J. Pierre, A. Boisivon, and L. Gutmann Alteration of PBP 3 entails resistance to imipenem in Listeria monocytogenes Antimicrob. Agents Chemother. 34 1990 1695 1698
44. P.E. Reynolds Structure, biochemistry and mechanism of action of glycopeptide antibiotics Eur. J. Clin. Microbiol. Infect. Dis. 8 1989 943 950
45. K. Hiramatsu Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance Lancet, Infect. Dis. 1 2001 147 155
46. F.C. Tenover, M.V. Lancaster, B.C. Hill, C.D. Steward, S.A. Stocker, G.A. Hancock, C.M. O'Hara, S.K. McAllister, N.C. Clark, and K. Hiramatsu Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides J. Clin. Microbiol. 36 1998 1020 1027
47. L. Cui, X. Ma, K. Sato, K. Okuma, F.C. Tenover, E.M. Mamizuka, C.G. Gemmell, M.N. Kim, M.C. Ploy, N. El-Solh, V. Ferraz, and K. Hiramatsu Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus J. Clin. Microbiol. 41 2003 5 14
48. T.D.H. Bugg, G.D. Wright, S. Dutka-Malen, M. Arthur, P. Courvalin, and C.T. Walsh Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA Biochemistry 30 1991 10408 10415
49. M.A. Cooper, M.T. Fiorini, C. Abell, and D.H. Williams Binding of vancomycin group antibiotics to d-alanine and d-lactate presenting self-assembled monolayers Bioorg. Med. Chem. 8 2000 2609 2616
50. D.H. Williams, A.J. Maguire, W. Tsuzuki, and M.S. Westwell An analysis of the origins of a cooperative binding energy of dimerization Science 280 1998 711 714
51. P.J. Loll, J. Kaplan, B.S. Selinsky, and P.H. Axelsen Vancomycin binding to low-affinity ligands: delineating a minimum set of interactions necessary for high-affinity binding J. Med. Chem. 42 1999 4714 4719
52. J. Kaplan, B.D. Korty, P.H. Axelsen, and P.J. Loll The role of sugar residues in molecular recognition by vancomycin J. Med. Chem. 44 2001 1837 1840
53. B. Perichon, P. Reynolds, and P. Courvalin VanD-type glycopeptide- resistant Enterococcus faecium BM4339 Antimicrob. Agents Chemother. 41 1997 2016 2018
54. M. Fines, B. Perichon, P. Reynolds, D.F. Sahm, and P. Courvalin VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405 Antimicrob. Agents Chemother. 43 1999 2161 2164
55. S.J. McKessar, A.M. Berry, J.M. Bell, J.D. Turnidge, and J.C. Paton Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis Antimicrob. Agents Chemother. 44 2000 3224 3228
56. L.M. Weigel, D.B. Clewell, S.R. Gill, N.C. Clark, L.K. McDougal, S.E. Flannagan, J.F. Kolonay, J. Shetty, G.E. Killgore, and F.C. Tenover Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus Science 302 2003 1569 1571
57. F.C. Tenover, L.M. Weigel, P.C. Appelbaum, L.K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C.M. O'Hara, L. Jevitt, J.B. Patel, and B. Bozdogan Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania Antimicrob. Agents Chemother. 48 2004 75 80
58. A. Severin, K. Tabei, F. Tenover, M. Chung, N. Clarke, and A. Tomasz High level oxacillin and vancomycin resistance and altered cell wall composition in Staphylococcus aureus carrying the staphylococcal mecA and the enterococcal vanA gene complex J. Biol. Chem. 279 2004 3398 3407
59. F. Van Bambeke Glycopeptides in clinical development: pharmacological profile and clinical perspectives Curr. Opin. Pharmacol. 4 2004 471 478
60. F. Van Bambeke, Y. Van Laethem, P. Courvalin, and P.M. Tulkens Glycopeptide antibiotics: from conventional molecules to new derivatives Drugs 64 2004 913 936
61. M.R. Leadbetter, S.M. Adams, B. Bazzini, P.R. Fatheree, D.E. Karr, K.M. Krause, B.M. Lam, M.S. Linsell, M.B. Nodwell, J.L. Pace, K. Quast, J.P. Shaw, E. Soriano, S.G. Trapp, J.D. Villena, T.X. Wu, B.G. Christensen, and J.K. Judice Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424) J. Antibiot. (Tokyo) 57 2004 326 336
62. D.R. Guay Dalbavancin: an investigational glycopeptide Expert Rev. Anti Infect. Ther. 2 2004 845 852
63. D.C. Hooper Mechanisms of action of antimicrobials: focus on fluoroquinolones Clin. Infect. Dis. 32 Suppl. 1 2001 S9 S15
64. P.G. Higgins, A.C. Fluit, and F.J. Schmitz Fluoroquinolones: structure and target sites Curr. Drug Targets 4 2003 181 190
65. C.J. Willmott, and A. Maxwell A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex Antimicrob. Agents Chemother. 37 1993 126 127
66. D.C. Hooper Mechanisms of fluoroquinolone resistance Drug Resist. Updat. 2 1999 38 55
67. F.J. Schmitz, P.G. Higgins, S. Mayer, A.C. Fluit, and A. Dalhoff Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance Eur. J. Clin. Microbiol. Infect. Dis. 21 2002 647 659
68. F.J. Schmitz, B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, M. Klootwijk, J. Verhoef, A. Fluit, H.P. Heinz, K. Kohrer, and M.E. Jones Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother. 41 1998 481 484
69. G.M. Eliopoulos Quinolone resistance mechanisms in pneumococci Clin. Infect. Dis. 38 Suppl. 4 2004 S350 S356
70. E.Y. Ng, M. Trucksis, and D.C. Hooper Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus Antimicrob. Agents Chemother. 40 1996 1881 1888
71. F.A. Browne, B. Bozdogan, C. Clark, L.M. Kelly, L. Ednie, K. Kosowska, B. Dewasse, M.R. Jacobs, and P.C. Appelbaum Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents Antimicrob. Agents Chemother. 47 2003 3815 3824
72. M.R. Jacobs, S. Bajaksouzian, A. Windau, P.C. Appelbaum, M.V. Patel, S.V. Gupte, S.S. Bhagwat, N.J. De Souza, and H.F. Khorakiwala In vitro activity of the new quinolone WCK 771 against staphylococci Antimicrob. Agents Chemother. 48 2004 3338 3342
73. M.V. Patel, N.J. De Souza, S.V. Gupte, M.A. Jafri, S.S. Bhagwat, Y. Chugh, H.F. Khorakiwala, M.R. Jacobs, and P.C. Appelbaum Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models Antimicrob. Agents Chemother. 48 2004 4754 4761
74. J.J. Vesely, F.D. Pien, and B.C. Pien Rifampin, a useful drug for nonmycobacterial infections Pharmacotherapy 18 1998 345 357
75. S.H. Gillespie Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective Antimicrob. Agents Chemother. 46 2002 267 274
76. D.H. Mariam, Y. Mengistu, S.E. Hoffner, and D.I. Andersson Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 48 2004 1289 1294
77. S. Ramaswamy, and J.M. Musser Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update Tuber. Lung Dis. 79 1998 3 29
78. M. Heep, U. Rieger, D. Beck, and N. Lehn Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis Antimicrob. Agents Chemother. 44 2000 1075 1077
79. A. Telenti, P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M.J. Colston, L. Matter, K. Schopfer, and T. Bodmer Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis Lancet 341 1993 647 650
80. P. Vannuffel, and C. Cocito Mechanism of action of streptogramins and macrolides Drugs 51 1996 S20 S30
81. B. Weisblum Erythromycin resistance by ribosome modification Antimicrob. Agents Chemother. 39 1995 577 585
82. P. Vannuffel, M. Di Giambattista, E.A. Morgan, and C. Cocito Identification of a single base change in ribosomal RNA leading to erythromycin resistance J. Biol. Chem. 267 1992 8377 8382
83. G. Wang, and D.E. Taylor Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide- streptogramin B antibiotics Antimicrob. Agents Chemother. 42 1998 1952 1958
84. J.I. Ross, E.A. Eady, J.H. Cove, C.E. Jones, A.H. Ratyal, Y.W. Miller, S. Vyakrnam, and W.J. Cunliffe Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associated with mutations in 23S rRNA Antimicrob. Agents Chemother. 41 1997 1162 1165
85. A. Canu, B. Malbruny, M. Coquemont, T.A. Davies, P.C. Appelbaum, and R. Leclercq Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae Antimicrob. Agents Chemother. 46 2002 125 131
86. R.R. Reinert, A. Wild, P. Appelbaum, R. Lutticken, M.Y. Cil, and A. Al-Lahham Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany Antimicrob. Agents Chemother. 47 2003 2319 2322
87. D.J. Farrell, I. Morrissey, S. Bakker, S. Buckridge, and D. Felmingham In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations Antimicrob. Agents Chemother. 48 2004 3169 3171
88. M. Kresken, B. Henrichfreise, S. Bagel, J. Brauers, and B. Wiedemann High prevalence of the ermB gene among erythromycin-resistant Streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin Antimicrob. Agents Chemother. 48 2004 3193 3195
89. S.M. Swaney, H. Aoki, M.C. Ganoza, and D.L. Shinabarger The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria Antimicrob. Agents Chemother. 42 1998 3251 3255
90. B. Bozdogan, and P.C. Appelbaum Oxazolidinones: activity, mode of action, and mechanism of resistance Int. J. Antimicrob. Agents 23 2004 113 119
91. C. Auckland, L. Teare, F. Cooke, M.E. Kaufmann, M. Warner, G. Jones, K. Bamford, H. Ayles, and A.P. Johnson Linezolid-resistant enterococci: report of the first isolates in the United Kingdom J. Antimicrob. Chemother. 50 2002 743 746
92. J. Prystowsky, F. Siddiqui, J. Chosay, D.L. Shinabarger, J. Millichap, L.R. Peterson, and G.A. Noskin Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci Antimicrob. Agents Chemother. 45 2001 2154 2156
93. V.G. Meka, and H.S. Gold Antimicrobial resistance to linezolid Clin. Infect. Dis. 39 2004 1010 1015
94. I.I. Raad, H.A. Hanna, R.Y. Hachem, T. Dvorak, R.B. Arbuckle, G. Chaiban, and L.B. Rice Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin Antimicrob. Agents Chemother. 48 2004 3583 3585
95. L. Xiong, P. Kloss, S. Douthwaite, N.M. Andersen, S. Swaney, D.L. Shinabarger, and A.S. Mankin Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action J. Bacteriol. 182 2000 5325 5331
96. M.I. Recht, S. Douthwaite, K.D. Dahlquist, and J.D. Puglisi Effect of mutations in the A site of 16S rRNA on aminoglycoside antibiotic-ribosome interaction J. Mol. Biol. 286 1999 33 43
97. M.I. Recht, and J.D. Puglisi Aminoglycoside resistance with homogeneous and heterogeneous populations of antibiotic-resistant ribosomes Antimicrob. Agents Chemother. 45 2001 2414 2419
98. Y. Suzuki, C. Katsukawa, A. Tamaru, C. Abe, M. Makino, Y. Mizuguchi, and H. Taniguchi Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene J. Clin. Microbiol. 36 1998 1220 1225
99. T. Prammananan, P. Sander, B.A. Brown, K. Frischkorn, G.O. Onyi, Y. Zhang, E.C. Bottger, and R.J. Wallace Jr. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae J. Infect. Dis. 177 1998 1573 1581
100. R.C. Cooksey, G.P. Morlock, A. McQueen, S.E. Glickman, and J.T. Crawford Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City Antimicrob. Agents Chemother. 40 1996 1186 1188
101. C. Katsukawa, A. Tamaru, Y. Miyata, C. Abe, M. Makino, and Y. Suzuki Characterization of the rpsL and rrs genes of streptomycin-resistant clinical isolates of Mycobacterium tuberculosis in Japan J. Appl. Microbiol. 83 1997 634 640
102. F. Bardou, C. Raynaud, C. Ramos, M.A. Lanéelle, and G. Lanéelle Mechanism of isoniazid uptake in Mycobacterium tuberculosis Microbiology 144 1998 2539 2544
103. H. Marrakchi, G. Laneelle, and A. Quemard InhA, a target of the antituberculosis drug isoniazid, is involved in a mycobacterial fatty acid elongation system, Fas-II Microbiology 146 2000 289 296
104. K. Mdluli, R.A. Slayden, Y. Zhu, S. Ramaswamy, X. Pan, D. Mead, D.D. Crane, J.M. Musser, and C.E. Barry III Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid Science 280 1998 1607 1610
105. L.A. Basso, R. Zheng, J.M. Musser, W.R. Jacobs Jr., and J.S. Blanchard Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates J. Infect. Dis. 178 1998 769 775
106. J.M. Musser, V. Kapur, D.L. Williams, B.N. Kreiswirth, D. van Soolingen, and J.D. van Embden Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance J. Infect. Dis. 173 1996 196 202
107. S.V. Ramaswamy, R. Reich, S.J. Dou, L. Jasperse, X. Pan, A. Wanger, T. Quitugua, and E.A. Graviss Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis Antimicrob. Agents Chemother. 47 2003 1241 1250
108. R.J. Heath, Y.T. Yu, M.A. Shapiro, E. Olson, and C.O. Rock Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis J. Biol. Chem. 273 1998 30316 30320
109. R.J. Heath, J.R. Rubin, D.R. Holland, E. Zhang, M.E. Snow, and C.O. Rock Mechanism of triclosan inhibition of bacterial fatty acid synthesis J. Biol. Chem. 274 1999 11110 11114
110. R.J. Heath, J. Li, G.E. Roland, and C.O. Rock Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene J. Biol. Chem. 275 2000 4654 4659
111. S.L. Parikh, G. Xiao, and P.J. Tonge Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid Biochemistry 39 2000 7645 7650
112. S. Sivaraman, J. Zwahlen, A.F. Bell, L. Hedstrom, and P.J. Tonge Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs Biochemistry 42 2003 4406 4413
113. W.H. Ward, G.A. Holdgate, S. Rowsell, E.G. McLean, R.A. Pauptit, E. Clayton, W.W. Nichols, J.G. Colls, C.A. Minshull, D.A. Jude, A. Mistry, D. Timms, R. Camble, N.J. Hales, C.J. Britton, and I.W. Taylor Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan Biochemistry 38 1999 12514 12525
114. G.E. Dale, C. Broger, A. D'Arcy, P.G. Hartman, R. DeHoogt, S. Jolidon, I. Kompis, A.M. Labhardt, H. Langen, H. Locher, M.G. Page, D. Stuber, R.L. Then, B. Wipf, and C. Oefner A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance J. Mol. Biol. 266 1997 23 30
115. A. Pikis, J.A. Donkersloot, W.J. Rodriquez, and J.M. Keith A conservative amino acid mutation in the chromosome-encoded dihydrofolate reductase confers trimethoprim resistance in Streptococcus pneumoniae J. Infect. Dis. 178 1998 700 706
116. R. de Groot, M. Sluijter, A. de Bruyn, J. Campos, W.H. Goessens, A.L. Smith, and P.W. Hermans Genetic characterization of trimethoprim resistance in Haemophilus influenzae Antimicrob. Agents Chemother. 40 1996 2131 2136
117. P. Huovinen, L. Sundström, G. Swedberg, and O. Sköld Trimethoprim and sulfonamide resistance Antimicrob. Agents Chemother. 39 1995 279 289
118. P.V. Adrian, C.J. Thomson, K.P. Klugman, and S.G. Amyes New gene cassettes for trimethoprim resistance, dfr13, and streptomycin-spectinomycin resistance, aadA4, inserted on a class 1 integron Antimicrob. Agents Chemother. 44 2000 355 361
119. O. Skold Resistance to trimethoprim and sulfonamides Vet. Res. 32 2001 261 273
120. H.S. Yu, J.C. Lee, H.Y. Kang, D.W. Ro, J.Y. Chung, Y.S. Jeong, S.H. Tae, C.H. Choi, E.Y. Lee, S.Y. Seol, Y.C. Lee, and D.T. Cho Changes in gene cassettes of class 1 integrons among Escherichia coli isolates from urine specimens collected in Korea during the last two decades J. Clin. Microbiol. 41 2003 5429 5433
121. E. Charpentier, and P. Courvalin Emergence of the trimethoprim resistance gene dfrD in Listeria monocytogenes Antimicrob. Agents Chemother. 41 1997 1134 1136
122. W. Sirawaraporn, T. Sathitkul, R. Sirawaraporn, Y. Yuthavong, and D.V. Santi Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase Proc. Natl. Acad. Sci. U. S. A. 94 1997 1124 1129
123. J. Yuvaniyama, P. Chitnumsub, S. Kamchonwongpaisan, J. Vanichtanankul, W. Sirawaraporn, P. Taylor, M.D. Walkinshaw, and Y. Yuthavong Insights into antifolate resistance from malarial DHFR-TS structures Nat. Struct. Biol. 10 2003 357 365
124. Y. Zhang, A. Scorpio, H. Nikaido, and Z. Sun Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide J. Bacteriol. 181 1999 2044 2049
125. M. Mestdagh, P.A. Fonteyne, L. Realini, R. Rossau, G. Jannes, W. Mijs, K.A. De Smet, F. Portaels, and E. Van den Eeckhout Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 43 1999 2317 2319
126. H.J. Marttila, M. Marjamaki, E. Vyshnevskaya, B.I. Vyshnevskiy, T.F. Otten, A.V. Vasilyef, and M.K. Viljanen pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia Antimicrob. Agents Chemother. 43 1999 1764 1766
127. T.S. Huang, S.S. Lee, H.Z. Tu, W.K. Huang, Y.S. Chen, C.K. Huang, S.R. Wann, H.H. Lin, and Y.C. Liu Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan Antimicrob. Agents Chemother. 47 2003 3672 3673
128. I. Portugal, L. Barreiro, J. Moniz-Pereira, and L. Brum pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal Antimicrob. Agents Chemother. 48 2004 2736 2738
129. X. Du, W. Wang, R. Kim, H. Yakota, H. Nguyen, and S.H. Kim Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii Biochemistry 40 2001 14166 14172
130. T.H. Farmer, J. Gilbart, and S.W. Elson Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus J. Antimicrob. Chemother. 30 1992 587 596
131. J. Gilbart, C.R. Perry, and B. Slocombe High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases Antimicrob. Agents Chemother. 37 1993 32 38
132. J.E. Hodgson, S.P. Curnock, K.G. Dyke, R. Morris, D.R. Sylvester, and M.S. Gross Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870 Antimicrob. Agents Chemother. 38 1994 1205 1208
133. B.D. Cookson The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice J. Antimicrob. Chemother. 41 1998 11 18
134. D.G. Thomas, J.M. Wilson, M.J. Day, and A.D. Russell Mupirocin resistance in staphylococci: development and transfer of isoleucyl-tRNA synthetase-mediated resistance in vitro J. Appl. Microbiol. 86 1999 715 722
135. M. Antonio, N. McFerran, and M.J. Pallen Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus Antimicrob. Agents Chemother. 46 2002 438 442
136. J. Turnidge, and P. Collignon Resistance to fusidic acid Int. J. Antimicrob. Agents 12 Suppl. 2 1999 S35 S44
137. S. Besier, A. Ludwig, V. Brade, and T.A. Wichelhaus Molecular analysis of fusidic acid resistance in Staphylococcus aureus Mol. Microbiol. 47 2003 463 469
138. S.M. Moskowitz, R.K. Ernst, and S.I. Miller PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A J. Bacteriol. 186 2004 575 579
139. J.B. McPhee, S. Lewenza, and R.E. Hancock Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa Mol. Microbiol. 50 2003 205 217
140. H. Lee, F.F. Hsu, J. Turk, and E.A. Groisman The PmrA-regulated pmrC gene mediates phosphoethanolamine modification of lipid A and polymyxin resistance in Salmonella enterica J. Bacteriol. 186 2004 4124 4133
141. J.M. Clements, F. Coignard, I. Johnson, S. Chandler, S. Palan, A. Waller, J. Wijkmans, and M.G. Hunter Antibacterial activities and characterization of novel inhibitors of LpxC Antimicrob. Agents Chemother. 46 2002 1793 1799
142. M.C. Pirrung, L.N. Tumey, C.R. Raetz, J.E. Jackman, K. Snehalatha, A.L. McClerren, C.A. Fierke, S.L. Gantt, and K.M. Rusche Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups J. Med. Chem. 45 2002 4359 4370
143. I. Chopra, L. Hesse, and A.J. O'Neill Exploiting current understanding of antibiotic action for discovery of new drugs J. Appl. Microbiol. 92 2002 4S 15S (Suppl.)
144. A.S. Waller, and J.M. Clements Novel approaches to antimicrobial therapy: peptide deformylase Curr. Opin. Drug Discov. Dev. 5 2002 785 792
145. P.S. Margolis, C.J. Hackbarth, D.C. Young, W. Wang, D. Chen, Z. Yuan, R. White, and J. Trias Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene Antimicrob. Agents Chemother. 44 2000 1825 1831
146. P. Margolis, C. Hackbarth, S. Lopez, M. Maniar, W. Wang, Z. Yuan, R. White, and J. Trias Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB Antimicrob. Agents Chemother. 45 2001 2432 2435
147. C. Giglione, and T. Meinnel Resistance to anti-peptide deformylase drugs Expert Opin. Ther. Targets 5 2001 415 418
148. S.D. Mills The role of genomics in antimicrobial discovery J. Antimicrob. Chemother. 51 2003 749 752
149. P.D. Stapleton, S. Shah, J.C. Anderson, Y. Hara, J.M. Hamilton-Miller, and P.W. Taylor Modulation of β-lactam resistance in Staphylococcus aureus by catechins and gallates Int. J. Antimicrob. Agents 23 2004 462 467